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INTRODUCTION
Allergic asthma is characterized by the intermediate pheno-
types of chronic inflammation of airway with predominant
eosinophilic infiltration, airway hyperresponsiveness, reversible
airway obstruction, and allergen specific IgE production. The
prevalence of asthma is increasing worldwide, also in Korea
(1). Asthma reduces the quality of life and may result in mor-
tality. It is regarded as one of most important public health
problems. The morbidity and mortality associated with asth-
ma are still increasing, especially during the last half 20th
century, despite the currently available mediations, which
demands new therapeutic modalities (2). Animal models are
essential in the study of the mechanisms of allergic diseases
and for the development of new therapies. The mouse is one
of the most popular species in the field of asthma study. It has
several advantages; a well-known immune system, the avail-
ability of many tools to manipulate the immunological pro-
cess, the availability of numerous genetically modified (trans-
genic or knockout) strains, and cost.
The persistence of a disease phenotype is important in the
evaluation of newly developed treatment modalities in animal
models. During the preclinical study, we evaluate whether
the treatment can reverse the established asthma phenotypes
in animal model. Many reports have been issued on mouse
models of asthma (3) but few have reported upon the long
term persistence of asthma phenotypes upon secondary allergen
challenge in previously sensitized and challenged mice. For
these reasons, we undertook to evaluate the persistence of asth-
ma phenotypes in a mouse model after secondary allergen chal-
lenge at different times after sensitization and initial challenge.
MATERIALS AND METHODS
Animals
Seven weeks old BALB/c female mice were used in this
study. The mice were purchased from Dae Han Biolink (Ch-
oongbuk, Korea) and kept in specific pathogen free conditions
in the Preclinical Center of the Clinical Research Institute of
Seoul National University Hospital (Seoul, Korea). None of
the mice was exposed to ovalbumin (OVA) before the experi-
ment. The study was approved by the Committee on Animal
Experimentation at our institution and performed according
to the guide for the care and use of laboratory animals issued
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Airway Inflammation and Allergen Specific IgE Production May
Persist Longer Than Airway Hyperresponsiveness in Mice
During the preclinical study of new therapeutic modality, we evaluate whether the
treatment can reverse the established asthma phenotypes in animal model. How-
ever, few have reported on the long term persistence of asthma phenotypes upon
re-challenge with allergen (secondary challenge) in animal model. We evaluated
the persistence of asthma phenotypes by secondary challenge at different times
in previously challenged murine asthma model. BALB/c mice sensitized by intraperi-
toneal injections of 20  g of ovalbumin and 1 mg of alum on days 1 and 14 were
challenged initially by the inhalation of 1% ovalbumin for 30 min on days 21, 22,
and 23. Each group of mice was rechallenged at 5, 7, 9, or 12 weeks after the
initial challenge. Airway hyperresponsiveness, BAL fluid, airway histology and
serum ovalbumin-specific IgE level were evaluated. Airway eosinophilia, airway
inflammation and serum ovalbumin-specific IgE production persisted upon sec-
ondary allergen challenges at least 12 weeks after the initial challenge. However,
airway hyperresponsiveness persisted only until mice were rechallenged 7 weeks
after the initial challenge. Airway inflammation and allergen specific IgE production
may persist longer than airway hyperresponsiveness in a mouse asthma model
of secondary allergen challenge.
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by the Institute of Laboratory Animal Resources Commission
on Life Sciences, National Research Council, U.S.A. (4).
Experimental protocol
The protocol used for sensitization and bronchial challenge
was the same as previously described (5). There were five groups
and each group consists of five mice; mice initially challenged,
mice initially challenged and rechallenged at 5, 7, 9, or 12
weeks after the initally challenge (Fig. 1). Mice were sensitized
by intraperitoneal injections of 20  g of ovalbumin (OVA,
ICN, Costa Mesa, U.S.A.) with 1 mg of alum hydroxide (alum,
Sigma, St. Louis, U.S.A.) on days 1 and 14. The initial inhala-
tion challenge was done with 1% OVA for 30 min daily on
days 21, 22 and 23 with an ultrasonic nebulizer (NE-U12,
Omron, Japan). Each group of mice were rechallenged at dif-
ferent times (5, 7, 9, or 12 weeks after the initial challenge)
with 1% OVA for 30 min daily and for 3 consecutive days.
Mice sensitized and challenged by PBS at each time were used
as negative controls for possible environmental factors.
Evaluation of asthma phenotypes
Airway hyperresponsiveness: Twenty-four hours after the
final OVA inhalation, airway hyperresponsiveness was assessed
by methacholine-induced airflow limitation using single cham-
ber whole body plethysmography (Allmedicus, Anyang, Korea)
as previously described (5, 6). Increases in enhanced pause
(Penh) were measured as an index of airway resistance {Penh=
[(Te/RT-1)×(PEF/ PIF)], where Penh=enhanced pause, Te=
expiratory time (s), RT=relaxation time (s), PEF=peak expi-
ratory flow (mL/s), PIF=peak inspiratory flow (mL/s)}. Increas-
ing doses of methacholine (ranging from 2.5 to 50 mg/mL;
Sigma, St. Louis, U.S.A.) were administered by nebulization
for 3 min, and the values of Penh were calculated over the fol-
lowing 3 min. During the experiment, the activity of the mice
and the barometric plethysmograph flow tracings were moni-
tored. For the quantification of the dose-response to metha-
choline, the linear regression of Penh on log was calculated
for individual mice. The log dose corresponding to an increase
in Penh of 200%, respectively, was determined, and the aver-
age log doses of the different groups were compared. The results
are presented as PC200, which is the concentration of metha-
choline required to increase the baseline Penh by 200%.
Inflammatory cells in bronchoalveolar lavage (BAL) fluid:
Forty-eight hours after the final OVA challenge, mice tracheae
were cannulated and the lungs were lavaged five times with
0.4 mL aliquots of pyrogen-free saline. After Diff-quickR stain-
ing (Dade Behring AG, Dudingen, Switzerland) of lung lavage
cells in a cytospin preparation, two investigators blindly count-
ed more than 300 inflammatory cells under a light microscope
and classified them as macrophages, lymphocytes, neutrophils,
or eosinophils.
Lung histology: Following BAL, the lungs were infused
with 10% formalin and embedded in paraffin. Lung sections
were stained with hematoxylin and eosin. Slides were assessed
by light microscopy and the degree of peribronchial and perivas-
cular inflammation was evaluated on a subjective scale of 0-
3, as previously described (5, 7). The investigators who scored
airway inflammation were blinded as to which preparation
they were scoring. Briefly, a value of 0 was assigned when no
inflammation was detectable, a value of 1 for occasional cuff-
ing with inflammatory cells, a value of 2 when most bronchi
or vessels were surrounded by a thin layer (one to five cells)
of inflammatory cells and a value of 3 when most bronchi or
vessels were surrounded by a thick layer (more than five cells
deep) of inflammatory cells. The total lung inflammation was
defined as the average of the peribronchial and perivascular
inflammation scores.
Serum ovalbumin specific IgE: Forty-eight hours after the
final OVA challenge, blood samples were obtained from the
mice via the inferior vena cava. Anti-OVA specific antibodies
were measured by ELISA, as previously described (5). Briefly,
microtiter plates (Nunc, Roskilde, Denmark) were coated
overnight with 2  g/mL of OVA in a 50 mM of carbonate
buffer (pH 9.6) at 4℃Nonspecific binding was blocked with
2% bovine serum albumin for 1 hr at 20℃After incubation
of the test sera for 2 hr, the plates were incubated with horse-
radish peroxidase-labeled goat anti-mouse IgE (Pharmingen,
San Diego, U.S.A.) for 1 hr at 20℃. The reaction was devel-
oped with a tetramethylbenzidine (Sigma, St. Louis, U.S.A.)
and stopped by adding 2 N H2SO4. The optical density was
measured at 490 nm, and the antibody titers of the samples
were related to pooled standards, which were generated in the
laboratory; results are expressed in arbitrary units (AU) accord-
ing to each O.D. value.
OVA 20  g+alum 1 mg
IP (x2)
1% OVA inhalation
Initial
Challenge, 0 5 7 9 12 wk
Secondary
Challenge,
0   1   2   3   4   5   6   7   8   9  10  11  12  13  14  15 wk
Fig. 1. Experimental protocols for sensitization, initial challenge and
secondary challenge. 7-week old female BALB/c mice were used
for the experiment. Mice were sensitized by intraperitoneal injection
and initial provocative challenge was done on days 21, 22, 23 (0
week). Secondary challenges were performed at 5, 7, 9, or 12
weeks after the initial challenge. PBS treated mice were used as
controls. Five mice were used in each group. IP: intraperitoneal
injection.Airway Inflammation, IgE and Airway Hyperresponsivenss 71
Statistical Analysis
Statistical analysis was performed using the Kruskal-Wallis
and the Mann-Whitney U tests. Statistical significance was
accepted at p<0.05. Analysis was performed using SPSS 9.0.
Data are expressed as the means±standard error with the
exception of the inflammatory scores, which are expressed as
the means±standard deviation.
RESULTS
Airway hyperresponsiveness
Airway hyperresponsiveness upon a secondary OVA chal-
lenge was persistent when mice were rechallenged 5 or 7 weeks
after the initial inhalation challenge. The values of PC200 ob-
served in the rechallenged animals at 5, or 7 weeks after the
initial challenge were similar to that of initially challenged
group (5.30±0.30, 10.6±3.50 vs. 7.37±3.63 mg/mL,
p>0.05), but the values of PC200 at 9 and 12 weeks after the
initial challenge were higher than that of initially challenged
group (30.20±11.60, 19.5±15.2 vs. 7.37±3.63 mg/mL,
p<0.05).
Mice sensentized and challenged with PBS showed con-
stantly high values of PC200 from the initial challenge (41.30
±8.67, 39.3±10.7, 33.48±10.2, 41.49±8.50, 45.20±
4.80 mg/mL, p>0.05), which means that there was no envi-
ronmal factor that may alter the physiological air flow dur-
ing the experiment (Fig. 2). 
Bronchoalveolar lavage fluid (BALF)
The percentages of BALF eosinophils in the secondarily
challenged mice were higher even in mice that were rechal-
lenged 12 weeks after initial challenge. The proportions of
BALF eosinophils observed in the rechallenged animals at 5,
7, 9, or 12 weeks after the initial challenge were similar to
that of initially challenged group (37.8±9.7, 34.7±4.6,
29.4±9.1, 23.3±6.0 vs. 39.6±9.3 %, p>0.05). PBS treated
mice showed no eosinophil in BAL fluid at initial challenge
and even at the end of the study (0.0±0.0 %). (Fig. 3A)
Histopathology of the lung
The degree of inflammation was evaluated in 10 random
high power fields (×400). Peribronchial, perivascular and
total inflammation scores in the rechallenged animals at 5,
7, 9, or 12 weeks were similar to that of initially challenged
group (p>0.05). The inflammatory scores of PBS treated mice
were lower than those of OVA treated mice (p<0.05) (Fig. 3B).
Epithelial shedding was not found and the thickness of subep-
ithelial fibrosis was similar in all groups.
Fig. 2. Airway hyperresponsiveness upon a secondary OVA chal-
lenge is persistent when mice were rechallenged 5 or 7 weeks
after the initial inhalation challenge. However, airway hyperrespon-
siveness disappeared when mice were rechallenged 9 or 12 weeks
after the initial challenge. The results are presented as PC200 values,
where PC200 is the concentration of methacholine required to incr-
ease the baseline Penh by 200%.
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Fig. 3. (A) The proportion of eosinophils in bronchoalveolar lavage fluid. Eosinophils are increased even when mice were rechallenged
12 weeks after the initial challenge. (*p<0.05, compared to the PBS treated mice, BALF: bronchoalveolar lavage fluid). (B) The degrees of
airway inflammation observed in the initially and rechallenged animals at 5, 7, 9, or 12 weeks after the initial challenge are similar each other
and higher than that of the PBS treated mice. Total lung inflammation was defined as the average value of the peribronchial and perivascu-
lar inflammation scores. (*p<0.05, compared to initially challenged mice).
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Serum OVA specific IgE
The serum anti-OVA specific IgE level was still increased
when mice were rechallenged 12 weeks after the initial chal-
lenge. The levels of serum anti-OVA specific IgE observed
in the rechallenged animals at 5, 7, 9, or 12 weeks were not
different to that of initially changed group (72.8±24.7, 18.0
±5.6, 65.2±45.8, 21.5±5.0 vs. 50.2±12.1 A.U., p>0.05).
We could not detect serum OVA-specific IgE production in
PBS treated mice (0.0±0.0 A.U.) (Fig. 4).
DISCUSSION
In this study, we found that eosinophilic airway inflamma-
tion and the increased serum allergen-specific IgE production
persisted upon a secondary challenge at least 12 weeks after
the initial challenge in a murine model of asthma. Airway
hyperresponsiveness, another characteristic of asthma, persisted
when asthmatic mice were reexposed to allergen only 5 to 7
weeks after the initial challenge. 
It is important to determine the duration of a persistent
disease phenotype in an experimental protocol. The majority
of previous investigations have examined the effects of ther-
apeutic intervention at the time of sensitization or before the
initiation of allergic responses in mouse models (5, 8-10).
However, we see patients who have established asthma in a
clinical situation. Therefore, we should be aware as to whether
the therapeutic intervention can reverse the established asth-
ma phenotypes. In this study, we evaluated the persistence
of asthma phenotypes upon a secondary challenge in previ-
ously challenged murine asthma model.
The persistence of asthma phenotypes might vary accord-
ing to the experimental protocols used, especially in terms
of the types and dosages of allergens, adjuvants, and the strains
of mice. We chose ovalbumin, alum, and BALB/c mice because
they are one of the most popular systems used in asthma study
(3). It has been reported that asthma phenotypes, including
airway hyperresponsiveness persist for at least 7 weeks in a
mouse model of asthma using ragweed allergen. However, the
study used a different allergen and three ragweed challenges
were performed during the experiment (11). Another study
revealed that eosinophilic inflammation of airways persisted
for 8 weeks in a mouse model of asthma using ovalbumin (10).
Recently, Kanehiro et al. (12) rechallenged previously chal-
lenged animals 6 weeks after the initial challenge using oval-
bumin, and measured airway resistance and dynamic compli-
ance in anesthetized, mechanically ventilated mice. They found
that airway hyperresponsiveness and eosinophilic inflamma-
tion of airway persisted.
We evaluated the persistence of asthma phenotypes over a
longer period with different model system. Though our results
concur with those of the previous reports in similar period
(10-12), we found that airway hyperresponsiveness upon a
secondary challenge disappeared when mice were reexposed
to allergen 9 or 12 weeks after initial challenge. However, air-
way eosinophilia (IL-5 dependent) and serum allergen specific
IgE production (IL-4 dependent) were found to be elevated
when mice were rechallenged even 12 weeks after the initial
challenge. This finding suggests that the airway inflammation,
allergen-specific IgE production and airway hyperresponsive-
ness may be regulated by different mechanisms.
Airway hyperresponsiveness is a characteristic feature of
asthma and is used as an index of the asthma phenotype in a
mouse model (3). Airway inflammation, airway wall thick-
ening, airway epithelial damage, edema of the airways, alter-
ation of presynaptic control of acetylcholine release, activation
of local axonal reflexes, altered airway smooth muscle function,
or a combination of several of these events have been suggested
as possible mechanisms of airway hyperresponsiveness (13).
As for the cytokines, there was initial confusion about the
relative importance of IL-4 and IL-5 in the pathogenesis of
airway hyperresponsiveness (3). Anti-IL-4 antibody treatment
reduced airway hyperresponsiveness in sensitized BALB/c
mice without affecting airway eosinophilia while anti-IL-5
antibody did not reduce the airway hyperresponsiveness in
one study (14), but deleting the IL-5 gene in C57BL/6 mice
was found to abolish their ability to generate airway hyper-
responsiveness and tissue eosinophilia in another (15). Now,
three distinct pathways leading to airway hyperresponsive-
ness after T cell activation have been suggested (3). First, the
IL-4 dependent pathway, which involves that IgE-stimulat-
ed activation of mast cells discharge mediators, such as his-
tamine and leukotrienes that induce airway hyperresponsive-
ness upon exposure to the allergen (16). Second, the IL-5 de-
pendent pathway, which involves allergen-activated T cell
release of IL-5 that promotes eosinophil mediated epithelial
cell damage and airway hyperresponsiveness (16). Finally, the
IL-4 and IL-5 independent pathway, which involves a novel
CD4+ T cell pathway for modulating airway hyperrespon-
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Fig. 4. The serum ovalbumin specific IgE level is still increased
when mice were rechallenged 12 weeks after the initial challenge.
The level of the specific IgE in the initially challenged or rechallenged
mice are similar (p>0.05, by Kruskal-Willis test) and higher than
that of PBS treated group (*p<0.05, compared to all allergen chal-
lenged groups). Sera of four to five mice were evaluated in each
group. BALF: bronchoalveolar lavage fluid.siveness, was suggested to function in IL-4- and IL-5- defi-
cient BALB/c mice (17). IL-13 shares a common alpha chain
with IL-4 and enhances IgE production, mucus production,
and eotaxin expression (3, 18). It has been reported that IL-
13 can induce airway hyperresponsiveness independent of
serum allergen-specific IgE, airway eosinophilia, IL-4, and
IL-5; blockade of IL-13 before the allergen provocation resulted
in decreased airway hypersensitivity without affecting airway
eosinophilic inflammation or serum ovalbumin specific IgE
level (18). IL-13 is important during antigen challenge, where-
as IL-4 is useful during sensitization (18). This finding is con-
cordant with our results. In the present study, no difference
was found in the extents of the mainly IL-5 dependent pro-
cesses (i.e., the proportion of eosinophils in BAL fluid, the
degree of airway inflammation, or epithelial damage) or in
the extent of the mainly IL-4 dependent process (i.e., serum
allergen-specific IgE level) in mice that were rechallenged at
different times. However, airway hyperresponsiveness persisted
for only 7 weeks after the initial challenge. Therefore, an IL-
4- and IL-5- independent regulatory mechanism, such as the
regulation of IL-13 or novel CD4+ T cell pathway, might be
involved in the modulation of airway hyperresponsiveness
upon secondary allergen challenge. However, the actual mech-
anism of this phenomenon remains to be elucidated.
We should admit that the number of mice in each group
might be small as this study was done as a preliminary exper-
iment before the evaluation of a new therapeutic modality.
There were some variation in the level of serum specific IgE
and the average value might seem to be somewhat decreased
in the last part of study. However, the levels of serum specific
IgE in the challenged or rechallenged mice were not statisti-
cally different by Kruskall-Willis test (p>0.05) and definitely
higher than that of PBS treated mice (p<0.05).
In summary, we report that airway inflammation and aller-
gen specific IgE production may persist longer than airway
hyperresponsiveness in a mouse asthma model of secondary
allergen challenge. It is important to know the persistence of
a disease phenotype in an animal model, especially in the eval-
uation of newly developed treatment modalities. This study
also supports the hypothesis that airway inflammation, aller-
gen-specific IgE production and airway hyperresponsiveness
may be regulated by different mechanisms.
REFERENCES
1. Kim YY, Cho SH, Kim WK, Park JK, Song SH, Kim YK, Jee YK,
Ha MN, Ahn YO, Lee SI, Min KU. Prevalence of childhood asthma
based on questionnaires and methacholine bronchial provocation test
in Korea. Clin Exp Allergy 1997; 27: 761-8.
2. Beasly R. The burden of asthma with specific reference to the United
States. J Allergy Clin Immunol 2002; 109 (Suppl 5): S482-9.
3. Leong KP, Huston DP. Understanding the pathogenesis of allergic
asthma using mouse models. Ann Allergy Asthma Immunol 2001; 87:
96-109.
4. Institute of laboratory animal resources, commission on life sciences,
National research council, USA Guide for the care and use of labo-
ratory animals. National academy press. Washington D.C. 1996.
5. Park YJ, Chang YS, Lee SW, Cho SY, Kim YK, Min KU, Kim YY,
Cho SH, Sung YC. The enhanced effect of a hexameric deoxyribogu-
anosine run conjugation to CpG oligodeoxynucleotides on the protec-
tion against allergic asthma. J Allergy Clin Immunol 2001; 108: 570-6.
6. Hamelmann E, Schwarze J, Takeda SK, Oshiba A, Larsen GL, Irvin
CG, Gelfand E. Noninvasive measurement of airway responsiveness
in allergic mice using barometric plethysmography. Am J Respir Crit
Care Med 1997; 156: 766-75.
7. Tournoy KG, Kips JC, Schou C, Pauwels RA. Airway eosinophilia
is not a requirement for allergen-induced airway hyperresponsiveness.
Clin Exp Allergy 2000; 30: 79-85.
8. Kline JN, Waldschmidt TJ, Businga TR, Lemish JE Weinstock JV,
Thorne PS, Krieg AM. Modulation of airway inflammation by CpG
oligodeoxynucleotides in a murine model of asthma. J Immunol 1998;
160: 2555-9. 
9. Broide D, Schwarze J, Tighe H, Gifford T, Nguyen MD, Malek S,
Van Uden J, Martin-Orozco E, Gelfand EW, Raz E. Immunostimula-
tory DNA sequences inhibit IL-5, eosinophilic inflammation, and air-
way hyperresponsiveness in mice. J Immunol 1998; 161: 7054-62. 
10. Shirota H, Sano K, Kikuchi T, Tamura G, Shirato K. Regulation of
murine airway eosinophilia and Th2 cells by antigen-conjugated CpG
oligodeoxynucleotides as a novel antigen-specific immunomodulator.
J Immunol 2000; 164: 5575-82.
11. Sur S, Wild JS, Choudhury BK, Sur N, Alam R, Klinman DM. Long
term prevention of allergic lung inflammation in a mouse model of
asthma by CpG oligodeoxynucleotides. J Immunol 1999; 162: 6284-93.
12. Kanehiro A, Ikemura T, Makela MJ, Lahn M, Joetham A, Dakhama
A, Gelfand EW. Inhibition of phosphodiesterase 4 attenuates airway
hyperresponsiveness and airway inflammation in a model of secondary
allergen challenge. Am J Respir Crit Care Med 2001; 163: 173-84.
13. O’Byrne PM. Airway hyperresponsiveness. In: Middletone E. Jr., et
al., editors. Allergy principles & practice. 5th ed., St. Louis: Mosby,
1998: 859-66.
14. Corry DB, Folkesson HG, Warnock ML, Erle DJ, Matthay MA, Wi-
ener-Kronish JP, Locksley RM. Interleukin 4, but not Interleukin 5 or
eosinophils, is required in a murine model of acute airway hyperre-
activity. J Exp Med 1996; 183: 109-17.
15. Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG. Interleukin
5 deficiency abolishes eosinophilia, airway hyperreactivity, and lung
damage in a mouse asthma model. J Exp Med 1996; 183: 195-201.
16. Drazen JM, Arm JP, Austen KF. Sorting out the cytokines of asthma.
J Exp Med 1996; 183: 1-5.
17. Hogan SP, Matthaei KI, Young JM, Koskinen A, Young IG, Foster
PS. A novel T cell-regulated mechanism modulating allergen-induced
airways hyperreactivity in BALB/c mice independently of IL-4 and
IL-5. J Immunol 1998; 161: 1501-09.
18. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL,
Donaldson DD. Interleukin-13: Central mediator of allergic asthma.
Science 1998; 282: 2258-61.
Airway Inflammation, IgE and Airway Hyperresponsivenss 73